SCHEMBL5206396

SCHEMBL5206396

C[Si](C)(C)CCOCn1nc(C#Cc2ccccn2)c2ccc(Nc3ccccc3C(=O)O)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 3/20 0.36
CTSL P07711 3/20 0.36
KDR P35968 1/20 0.35
AURKA O14965 2/20 0.33
AURKB Q96GD4 2/20 0.33
TTR P02766 1/20 0.33
CDC7 O00311 1/20 0.33
MAPK8 P45983 6/20 0.33
TAS2R14 Q9NYV8 2/20 0.33
NPC1 O15118 2/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5206522 0.93 ALOX15 (0.35) KDRAURKANPC1KDM4EALDH1A1
SCHEMBL5241802 0.79 POLB (0.34) NPC1L3MBTL1
SCHEMBL5206033 0.77 CNR2 (0.36) MEN1ALDH1A1KMT2A
SCHEMBL5207161 0.77 CTSV (0.36) CTSVCTSLTTRTAS2R14NPC1
SCHEMBL5207166 0.76 CTSV (0.35) CTSVCTSLKDRAURKAAURKB
SCHEMBL5249546 0.74 KDR (0.49) KDRAURKAAURKBMAPK8MAPT
SCHEMBL5249540 0.74 KDR (0.49) KDRAURKAAURKBMAPK8MAPT
SCHEMBL5206096 0.71 KDR (0.49) CTSVCTSLKDRAURKBMAPK8
SCHEMBL5207031 0.69 MAPT (0.36) KDRAURKANPC1KDM4EMEN1
SCHEMBL5207035 0.69 MAPT (0.36) KDRAURKANPC1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 EP disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 US disclosed
US-7053107-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-30 US disclosed
EP-1585743-A1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER INC. (US) 2005-10-19 EP disclosed
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-30 US disclosed
WO-2004056806-A1 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES PFIZER INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 CTSV 3738/4885CTSL 4263/4885KDR 88/4885
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 CTSV 3738/4885CTSL 4263/4885KDR 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.